Amyotrophic Lateral Sclerosis Companies

Top Industry Leaders in the Amyotrophic Lateral Sclerosis Market

Amyotrophic Lateral Sclerosis Key Companies.jpg Disclaimer: List of key companies in no particular order

October 2023: Phase II clinical trial of NLRP3 inhibitor "ZYIL1" in patients with Amyotrophic Lateral Sclerosis (ALS) has been approved by the Central Drugs Standard Control Organisation (CDSCO), Government of India. They believe that ZYIL1 will provide new avenues for treating ALS by reducing neuroinflammation and neurodegeneration. Neuroinflammation and fast neurodegeneration cause ALS sufferers to gradually lose the capacity to move, speak, eat, and breathe. Loss of motor neurons in the brain and spinal cord, which regulate voluntary muscle movement, is a hallmark of amyotrophic lateral sclerosis. Safety, tolerability, pharmacokinetics, and pharmacodynamics in ALS patients will be investigated in a Phase II clinical research. The main goal of this Phase 2 placebo-controlled, randomized, double-blind clinical study is the change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at Weeks 4, 8, and 12.

October 2023: In order to speed up the development of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS), BrainStorm Cell therapies Inc., a leading producer of adult stem cell therapies for neurodegenerative illnesses, has announced a strategic realignment. To further the development of treatments for amyotrophic lateral sclerosis (ALS), the company plans to 1) conduct a double-blind, placebo-controlled Phase 3b clinical trial for NurOwn in the United States with an open-label extension, and 2) maintain the publication of data from the Phase 3 clinical trial on biomarkers, long-term safety, and survival. However, the experiment did show a clinically relevant response in a pre-specified cohort of patients with less advanced illness, which may help explain why the ALSFRS-R scale had trouble measuring disease progression in individuals with severe ALS.

List of Amyotrophic lateral sclerosis Key companies in the market